Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial¶
Bresalier. (2005). Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. New England Journal of Medicine.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Adverse Drug Event
- Accumulating post-market data and the APPROVe trial revealed that long-term use roughly doubled the rate of confirmed thrombotic cardiovascular events (relative risk 1.92, 95% CI 1.19–3.11), a composite driven jointly by myocardial infarction and ischaemic cerebrovascular events
This sourceThe APPROVe trial, in which three years of rofecoxib roughly doubled the rate of confirmed thrombotic cardiovascular events against placebo — 1.50 against 0.78 per 100 patient-years, relative risk 1.92 (95% CI 1.19-3.11) — on a composite endpoint driven jointly by myocardial infarction and ischaemic cerebrovascular events.
- Accumulating post-market data and the APPROVe trial revealed that long-term use roughly doubled the rate of confirmed thrombotic cardiovascular events (relative risk 1.92, 95% CI 1.19–3.11), a composite driven jointly by myocardial infarction and ischaemic cerebrovascular events
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:9e9c0aa728bb · see in the full table